AMR: ENABLE selects Mutabilis candidate

  07 November 2019

A new oral combination treatment that might overcome  beta-lactam / fluoroquinolone co-resistance has now been selected for accelerated preclinical development by the Portfolio Management Committee of ENABLE, a programme under the Innovative Medicines Initiative’s (IMI) New Drugs 4 Bad Bugs (ND4BB) portfolio.

Authors: tg
Smart Innovations  

Display your AMR technology / product:

Global AMR Technologies Database

  • Preventive – Diagnostic – Antimicrobial technologies
  • Academia – Research Institutes – Start ups – SMEs – Multinationals
  • Early research <-> near market (max 5)
  • Global reach for funding / co-development / licensing
  • No costs (until year end 2019)

Festive Launch Database 19 Nov Symposium Dinner ‘Emerging Antimicrobials and Diagnostics in AMR 2019
Click to join the Symposium Dinner (to join the Symposium separate registration obligatory)

Display your technology >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!